Revenue segments as reported by the company.

Product revenue

Service and other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Goodwill Impairment

Restructuring costs

Intangible assets and other long-lived assets impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bionano Genomics

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bionano Genomics reports robust Q1 performance and strategic growth plans

Bionano Genomics demonstrated strong revenue growth and operational progress in Q1 2024.
While facing short-term revenue challenges, the company's strategic initiatives and product advancements position it for long-term success.
Efforts to reduce expenses and expand the customer base underscore Bionano's commitment to sustainable growth.

Bionano Genomics reports Q2 revenue decline, focuses on growth strategies

Bionano Genomics faced revenue decline in Q2 2024, attributed to discontinued services and challenges in China.
Despite operational streamlining efforts, the company aims to drive growth through product advancements and partnerships.
Lowered revenue guidance underscores the need for strategic adjustments to navigate market challenges and optimize performance.

Bionano Genomics reports Q3 revenue decline but shows cost efficiency

Bionano Genomics showcased operational improvements with cost reductions and growth in key metrics despite a revenue decline.
The company's focus on expense reduction, revenue growth, and profitability sets a strategic direction for future success.
Challenges persist in revenue generation and cost management, but opportunities in technology adoption and market expansion are evident.
Overall, Bionano Genomics aims to balance financial stability with growth initiatives to drive long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bionano Genomics' (BNGO) CEO Erik Holmlin on Q4 2021 Results - Earnings Call Transcript

Bionano Genomics (NASDAQ:BNGO) is a life sciences instrumentation company focused on the genome analysis space. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions.

Bionano Genomics Has Attractive Applications But An Unattractive Stock Price

SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 1st, 2022 at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2021 and to highlight recent corporate progress.

Bionano Genomics to Report Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call and Webcast on March 1st, 2022

Bionano's Saphyr appears to be able to help doctors treat leukemia more effectively, and adoption of its device is growing rapidly. BNGO stock is a buy.

Bionano Stock Looks to Have a Monster Comeback in Its Future

The newly proposed workflow has 93% success rate compared to 9.6% success rate of traditional methods by eliminating cell culture, replacing karyotyping analysis with OGM for comprehensive SV analysis of fetal tissue and adding chromosomal microarray analysis of formalin-fixed, paraffin-embedded POC tissue to recover samples contaminated with maternal cells. The newly proposed workflow has 93% success rate compared to 9.6% success rate of traditional methods by eliminating cell culture, replacing karyotyping analysis with OGM for comprehensive SV analysis of fetal tissue and adding chromosomal microarray analysis of formalin-fixed, paraffin-embedded POC tissue to recover samples contaminated with maternal cells.

Bionano Genomics Announces First Publication Demonstrating OGM as an Alternative to Karyotyping for Product of Conception Sample Analysis

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solution for visualization, interpretation and reporting of genomic data, announced today that company management will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Erik Holmlin, PhD, Bionano's president and chief executive officer, is scheduled to participate in a fireside chat on Wednesday, February 16th, 2022 at 2:30 pm ET. BTIG hosted events are intended for prospective and existing BTIG clients. To listen to the live event, please contact your BTIG representative with interest.

Bionano Genomics to Present at the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

A preliminary report from Bionano Genomics doesn't tell the full story and a lack of profitability will likely weigh on BNGO stock. The post Investors Have Cast Their ‘No' Votes Against Bionano Genomics appeared first on InvestorPlace.

Investors Have Cast Their ‘No' Votes Against Bionano Genomics

Bionano's recent results are lackluster and point to more volatility ahead for BNGO stock. Best to just avoid this stock for now.

Bionano Is Not the Genomics Stock To Bet On

As a nascent company with massive potential in genetic testing, Bionano Genomics, Inc. stands to gain as its OGM technology has been found complementary to other NGS technologies.

Bionano Stock: The Delicate Balance Between Growth And Share Dilution

SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, today announced the adoption of its Saphyr system by two genetics laboratory hubs (GLH) within the United Kingdom's (UK) National Health Service (NHS). The Newcastle upon Tyne Hospitals NHS Foundation Trust and the Birmingham Women's and Children NHS Foundation Trust intends to utilize the system to evaluate OGM against traditional cytogenetic methods.

Bionano Genomics Announces UK Footprint Expansion with Adoption of its Saphyr® System for Optical Genome Mapping in Two Genetic Laboratory Hubs within the United Kingdom's National Health Service

Intercept Pharma

Ocugen, Inc.

Vaxart

Select analysts and investment banks believe these little-known companies can skyrocket.

4 Under-the-Radar Stocks With 319% to 645% Upside in 2022, According to Wall Street

SAN DIEGO, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data today announced the publication of a study that evaluated the performance and clinical utility of combining OGM and a 523-gene next-generation sequencing (NGS) panel for comprehensive evaluation of myeloid tumors and compared it to standard cytogenetic methods (karyotyping and fluorescence in situ hybridization (FISH) and a 54-gene NGS panel.

Bionano Genomics Announces Publication of the First Study to Combine OGM and NGS to Evaluate Myeloid Cancers

BNGO Stock is a play in the burgeoning gene sequencing market at scale, not at home. That's worth understanding and potentially purchasing.

Bionano Genomics Is Interesting as Genome Testing Scales Upwards

SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, today announced that it will financially support the ACMG Foundation for Genetic and Genomic Medicine and its Next Generation Fellowship & Residency Training Awards Program in genetics and genomics.

UPDATE -- Bionano Genomics Announces its Support for the ACMG Foundation for Genetic and Genomic Medicine and its Next Generation Fellowship & Residency Training Awards Program

Bionano Genomics Announces its Support for the AGMG Foundation for Genetic and Genomic Medicine and its Next Generation Fellowship & Residency Training Awards Program

SAN DIEGO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, capped off the last day of 2022 Symposium, the Company's premiere event showcasing OGM research applications across key clinical areas of constitutional genetic disease, hematologic malignancies, solid tumors and OGM combined with next-generation sequencing (NGS).

Bionano Genomics Hosts Final Day of 2022 Symposium with Presentations Demonstrating the Combined Detection Power of OGM and NGS

The stock price of BioNano Genomics Inc (NASDAQ: BNGO) increased by 1.46% today. This is why it happened.

BioNano Genomics Stock (BNGO): Why The Price Went Up Today

SAN DIEGO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, hosted the third day of 2022 Symposium, the Company's premiere event showcasing OGM research applications across key clinical areas of constitutional genetic disease, hematologic malignancies, solid tumors and OGM combined with next-generation sequencing (NGS).

Bionano Genomics Hosts Day 3 of 2022 Symposium with New Research Demonstrating Applications of OGM in Solid Tumor Analysis

Bionano Genomics Inc (NASDAQ: BNGO) posted preliminary Q4 sales of $5.8 million - $6.2 million, +25% - 33% sequentially, up 45% - 55% Y/Y, and above the consensus of $5.44 million. FY21 revenue is expected to be $17.5 million - $17.9 million (consensus $17.13 million), more than doubled from FY20.

Bionano Genomics Preliminary Q4, FY21 Revenue Exceed Expectations

- Preliminary Q4 revenue expected between $5.8 and $6.2 million; 45%-55% increase over Q4 2020

Bionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2021 Results

SAN DIEGO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, hosted the second day of 2022 Symposium, the Company's premiere event showcasing OGM research applications across key clinical areas of constitutional genetic disease, hematologic malignancies, solid tumors and OGM combined with next-generation sequencing (NGS).

Bionano Genomics Hosts Day 2 of 2022 Symposium with New Research Demonstrating How OGM Detects Known and Novel Variants in Hematologic Malignancies

SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting of genomic data, hosted today the first of four days of 2022 Symposium, the Company's premiere event showcasing OGM research applications across key clinical areas of constitutional genetic disease, hematologic malignancies, solid tumors and OGM combined with next-generation sequencing (NGS).

UPDATE - Bionano Genomics Hosts Day 1 of 2022 Symposium with Six Presentations Highlighting the Superior Performance of OGM in Variant Detection for Constitutional Genetic Diseases

Bionano Genomics Hosts Day 1 of 2022 Symposium with Six Presentations Highlighting the Superior Performance of OGM in Variant Detection for Constitutional Genetic Diseases

AYRO

iCAD

Quantum Computing

Safe-T Group Ltd - ADR

Electrameccanica

These cheap stocks under $10 are poised to rally in the new, more friendly macro environment that's in place as 2022 unfolds. The post 7 of the Best Cheap Stocks Under $10 for 2022 to Buy Now appeared first on InvestorPlace.

7 of the Best Cheap Stocks Under $10 for 2022 to Buy Now

Even though BNGO stock investors struggled in 2021, prepare for new price discovery as Bionano pushes the envelope in optical genome mapping. The post Bionano Genomics Stock Is a Low-Priced Bet on Sound Science appeared first on InvestorPlace.

News for Bionano Genomics Stock (BNGO)